| Dermatitis |
1 |
1 |
| Atopic Dermatitis |
0 |
0.62 |
| Pain Management |
0 |
0.59 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.53 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.52 |
| HIV Infection |
0 |
0.52 |
| Europe |
0 |
0.39 |
| Food and Drug Administration (FDA) |
0 |
0.26 |
| Abdominal Pain |
0 |
0.23 |
| Abdomen |
0 |
0.13 |
| Acne |
0 |
0.13 |
| Adverse Effects |
0 |
0.13 |
| Blood |
0 |
0.13 |
| Clinician Health and Well-Being |
0 |
0.13 |
| Dizziness |
0 |
0.13 |
| Eczema |
0 |
0.13 |
| Grant |
0 |
0.13 |
| Headache |
0 |
0.13 |
| Medical Life |
0 |
0.13 |
| Nausea |
0 |
0.13 |
| Pain |
0 |
0.13 |
| Patient Safety |
0 |
0.13 |
| Pruritus |
0 |
0.13 |
| Severity Index |
0 |
0.13 |
| Skin and Soft Tissue Infection |
0 |
0.13 |
| UK Site Content |
0 |
0.13 |